Privi speciality chemicals Limited has successfully completed its strategic investment in a solar power project through a Special Purpose Vehicle (SPV), marking a significant step towards sustainable energy adoption. The company disclosed the completion of its equity investment in Radiance MH Sunrise Eleven Private Limited on March 10, 2026.

Investment Details and Structure

The investment represents the culmination of the Board's approval granted in July 2024 for participation in a solar power project. Privi Speciality Chemicals has entered into both a Power Purchase Agreement (PPA) and a Share Subscription and Shareholders Agreement (SSSHA) with the SPV.

Solar Power Project Specifications

The target entity, Radiance MH Sunrise Eleven Private Limited, is developing a substantial renewable energy facility in Maharashtra. The SPV was incorporated on March 12, 2021, under the Companies Act, 2013, and is currently in the development phase of its operations.

Strategic Objectives and Benefits

The investment aligns with Privi Speciality Chemicals' sustainability goals and cost optimization strategy. The company aims to become a captive user under the Electricity Act, 2003, and associated rules including the Electricity Rules, 2005.

Key strategic benefits include:

• Environmental Impact: Generation of power through environment-friendly resources
• Energy Independence: Reduced dependence on coal and natural gas
• Cost Optimization: Anticipated reduction in electricity costs for the company
• Regulatory Compliance: Alignment with captive user regulations under electricity laws

Regulatory Framework and Approvals

The transaction structure requires minimal initial regulatory approvals. However, post-commissioning of the solar power project, the SPV will need to obtain approval for long-term open access and installation of Availability Based Tariff (ABT) meter approval.

The investment does not constitute a related party transaction, and no promoter or group companies have any interest in the acquired entity. The transaction was completed as a cash consideration in a single tranche, demonstrating the company's commitment to its renewable energy strategy.

Privi Speciality Chemicals Limited conducted its Q3 and 9M FY26 earnings conference call on February 10, 2026, providing comprehensive insights into the company's strong financial performance and strategic growth initiatives. The management team, led by Chairman and Managing Director Mahesh Babani, outlined the company's resilient performance despite challenging global conditions and detailed expansion plans.

Strong Financial Performance Continues

The company demonstrated robust operational performance across key financial metrics for Q3FY26 and nine months ended December 31, 2025. The consolidated results reflect sustained growth momentum in the aroma chemicals segment.

Capacity Expansion and Strategic Roadmap

The management confirmed that Phase 1 capacity expansion is progressing as planned, with production capacity set to increase from 48,000 metric tons to 54,000 metric tons by March-April 2026. The company maintains its ambitious 5k:1k vision targeting ₹5,000 crores revenue and ₹1,000 crores EBITDA within 3-4 years.

Joint Venture Progress with Givaudan

Prigiv Specialties, the joint venture with Givaudan, achieved a significant milestone by turning EBITDA positive in Q3FY26. The partnership is strengthening with Givaudan providing ₹150 crores as non-interest bearing trade advance to reduce debt burden.

New Product Development and Innovation

The company is advancing its specialty chemicals portfolio with three new products under development. These include Maltol, Ethyl Maltol, Ethylene Brassylate, and notably, Cyclopentanone - which will be the world's first renewable resource-based production of this molecule.

Biotechnology and Sustainability Initiatives

The company is developing proprietary technologies for converting biomass into value-added products, with corn cob processing showing promising results. The technology has achieved 12% yield compared to industry standard of 10%, with plans for commercial scale implementation by 2028.

Market Positioning and Trade Benefits

Management highlighted significant advantages from evolving trade dynamics, particularly strengthening India-US-Europe trade arrangements. The company benefits from 18% duty advantages over Chinese competitors and zero duty in some cases, positioning it favorably in the global market.

Financial Health and Future Outlook

The company maintains strong financial discipline with debt-to-EBITDA ratio at 1.6x, well below the 2.5x ceiling. Management expressed confidence in sustaining EBITDA margins above 20%, with recent quarters delivering 25%+ margins. The planned ₹1,200 crores capex will be funded through internal accruals and debt without equity dilution.

The management emphasized the company's resilient business model in the essential aroma chemicals industry, supported by operational excellence, diversified product mix, and strategic expansion initiatives positioning it for sustained growth in the coming years.